Coronary Microvascular Disease Clinical Trial
— FREEDOMOfficial title:
A Double-Blind, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of CLBS16 in Subjects With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease
Verified date | October 2023 |
Source | Lisata Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial will explore the efficacy and safety of GCSF-mobilized autologous CD34+ cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single administration of CLBS16 or placebo.
Status | Terminated |
Enrollment | 34 |
Est. completion date | September 28, 2022 |
Est. primary completion date | September 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men or women age =18 - History of and currently experiencing angina at least 3 times per week - Prior diagnosis of CMD based on coronary flow reserve (CFR) = 2.5 or other measures - Canadian Cardiovascular Society (CCS) class II, III or IV chronic refractory angina - No obstructive coronary artery disease - On stable medical therapy for at least 30 days prior to enrollment - Must agree to use a reliable and acceptable method of contraception for the duration of participation - Written informed consent Exclusion Criteria: - Myocardial infarction within 90 days - Prior evidence of obstructive heart disease including PCI or CABG (or planned PCI or CABG) - Diagnosis of other specific cardiac disease - Must meet LVEF and GFR requirements - Current use of coumadin or DOACs - Hypersensitivity to GCSF, apheresis or study product components - Positive for HIV, hepatitis B or hepatitis C - Active inflammatory or autoimmune disease, or chronic immunosuppressive state - Drug abuse - Pregnant or lactating - Malignant neoplasm within 5 years - History of Sickle Cell Disease - Participation in another clinical study within 90 days prior to informed consent or concurrently with this study - Previous treatment with a CD34+ cell based therapy |
Country | Name | City | State |
---|---|---|---|
United States | Emory University Hospital | Atlanta | Georgia |
United States | The Christ Hospital | Cincinnati | Ohio |
United States | University of Florida - College of Medicine/ div of Cardiovascular Medicine | Gainesville | Florida |
United States | Memorial Regional Hospital | Hollywood | Florida |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | Minneapolis Heart Institute at Abbott Northwestern Hospital | Minneapolis | Minnesota |
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Lisata Therapeutics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in angina frequency | Baseline to 3 and 6 months | ||
Primary | Change from baseline in CCS angina class | Baseline to 3 and 6 months | ||
Primary | Change from baseline in total exercise time | Baseline to 6 months | ||
Primary | Change from baseline in health-related quality of life (HRQoL) | Baseline to 3 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06125392 -
Multicenter Registry on Microvascular Dysfunction - Searching a New Ach Spasm Definition
|
||
Recruiting |
NCT05805462 -
The Euro-CRAFT Registry
|
||
Recruiting |
NCT04598997 -
Artificial Intelligence With DEep Learning on COROnary Microvascular Disease
|
||
Completed |
NCT03104062 -
Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction
|
N/A | |
Completed |
NCT04202172 -
Functional Assessment of the Infart-related Artery With Bioactive and Polymer-free Coronary Stents (The FUNCOMBO Trial)
|
Phase 4 | |
Not yet recruiting |
NCT05793567 -
A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)
|
||
Completed |
NCT03523624 -
Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
|
||
Completed |
NCT02045459 -
Microvascular Disease Exercise Trial
|
N/A | |
Recruiting |
NCT05825339 -
Absolute Flow for Ischemia With No Obstructive Coronary Arteries
|
||
Recruiting |
NCT05178914 -
Personalized Medicine Using Coronary Microvascular Function Measured in Patient With Percutaneous Coronary Intervention in Angina
|
N/A | |
Active, not recruiting |
NCT04005963 -
The Value of PET Quantitative Analysis of Coronary Physiology in Coronary Microvascular Disease
|
||
Recruiting |
NCT05743140 -
A Clinical Study of Fundus OCTA for the Identification of CMD
|
||
Recruiting |
NCT03064295 -
Whole-Heart Myocardial Blood Flow Quantification Using MRI
|
||
Recruiting |
NCT03537586 -
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
|
N/A | |
Recruiting |
NCT04960371 -
Effects of Anxiety on Coronary Microcirculatory Function in Hypertensive Patients
|
||
Enrolling by invitation |
NCT05913999 -
Serial PET MPI in Patients Undergoing Cancer Treatment
|
||
Recruiting |
NCT05810051 -
Exercise and Coronary Microvascular Disease
|
N/A | |
Completed |
NCT05471739 -
Simultaneous Assessment of Coronary Microvascular Dysfunction and Ischemia With Non-obstructed Coronary Arteries With Intracoronary Electrocardiogram and Intracoronary Doppler
|
||
Recruiting |
NCT04440761 -
Barts-MINOCA Registry
|
||
Completed |
NCT04685941 -
Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia
|
N/A |